



# FDA Guidances for Industry

- [\*Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials \(April 2022\)\*](#)
- [\*Inclusion of Older Adults in Cancer Clinical Trials \(March 2022\)\*](#)
- [\*Digital Health Technologies for Remote Data Acquisition in Clinical Investigations \(January 2022\)\*](#)
- [\*Enhancing the Diversity of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trial Designs \(November 2020\)\*](#)
- [\*Clinical Lactation Studies: Considerations for Study Design \(May 2019\)\*](#)
- [\*Postapproval Pregnancy Safety Studies \(May 2019\)\*](#)
- [\*Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials \(April 2018\)\*](#)
- [\*Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies \(September 2017\)\*](#)
- [\*Collection of Race and Ethnicity Data in Clinical Trials \(October 2016\) \(updated from September 2005\)\*](#)
- [\*E7 Studies in Support of Special Populations: Geriatrics \(August 1994\)\*](#)